Stockholders Approve Amended Equity Plan with Increased Annual Share Reserve

summarizeSummary

Oric Pharmaceuticals' stockholders approved an amended equity incentive plan that will allow for a higher annual share reserve for equity awards starting in 2027, increasing potential dilution, but also eliminated the ability to reprice awards.

check_boxKey Events

• Amended Equity Incentive Plan Approved

  Stockholders approved the Amended and Restated 2020 Equity Incentive Plan, effective June 18, 2026. This plan governs the issuance of stock options, restricted stock units, and other equity awards to employees and directors.

• Increased Annual Share Reserve for Equity Awards

  Starting with the 2027 fiscal year, the annual 'evergreen' provision for share increases will be 4% of outstanding shares, removing the previous annual cap of 2,656,500 shares. Based on current outstanding shares, this increases the potential annual share issuance from approximately 2.65 million to 4.14 million shares, representing a significant increase in potential dilution for existing shareholders.

• Elimination of Award Repricing Feature

  The amended plan eliminates the ability of the administrator to implement an 'Exchange Program,' which would have allowed for the repricing of outstanding awards. This is a positive governance change that protects shareholder value by preventing the lowering of exercise prices for underwater options.

• Routine Annual Meeting Results

  Stockholders re-elected Jacob M. Chacko, M.D. and Mardi C. Dier as Class III directors, ratified KPMG LLP as the independent auditor, and approved executive compensation on an advisory basis, with future advisory votes on executive compensation to be held annually.

auto_awesomeAnalysis

Stockholders approved an amended equity incentive plan that significantly increases the potential annual share reserve for equity awards. While the percentage for the 'evergreen' provision was reduced from 5% to 4% of outstanding shares, the previous annual cap of 2,656,500 shares was removed for fiscal years starting in 2027. This change means the company can now issue approximately 4.14 million shares annually under this provision, up from the previous cap of 2.65 million shares, representing a substantial increase in potential annual dilution. On a positive note, the amendments also eliminate the ability of the plan administrator to implement an 'Exchange Program,' which would have allowed for the repricing or swapping of outstanding awards, a move that improves corporate governance by protecting shareholders from potential value destruction.